StoneX Group’s Acrivon Therapeutics ACRV Stock Holding History

StoneX Group’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43.1K	Buy	+22,573	New	+$42.9K	﹤0.01%	1631

Other funds holding ACRV

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

AAF Wealth Management Westborough, Massachusetts $275M AUM 17.17% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Redwood Park Advisors Redwood City, California $157M AUM 7.34% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

StoneX Group's ACRV Position: Q3 2026 in Review

StoneX Group opened a new position in Acrivon Therapeutics (ACRV) in Q3 2026: 22,573 shares worth $43.1K. The stake represents ﹤0.01% of the portfolio and ranks #1631 among its holdings.

11 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

StoneX Group held 22,573 shares of Acrivon Therapeutics worth $43.1K as of Q3 2026.
Acrivon Therapeutics was a new StoneX Group position in Q3 2026.
Acrivon Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1631 holding.
11 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.